<DOC>
	<DOCNO>NCT00042861</DOCNO>
	<brief_summary>RATIONALE : UCN-01 may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining UCN-01 chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine UCN-01 , fluorouracil , leucovorin treat patient metastatic unresectable solid tumor .</brief_summary>
	<brief_title>UCN-01 , Fluorouracil , Leucovorin Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose fluorouracil give combination UCN-01 leucovorin calcium patient metastatic unresectable solid tumor . - Determine clinical toxic effect regimen patient . - Determine pharmacokinetics drug patient . - Correlate , possible , pharmacokinetics drug clinical toxicity patient . - Assess pharmacodynamic effect drug patient . - Assess clinical activity regimen patient measurable disease . OUTLINE : This dose-escalation study fluorouracil ( 5-FU ) . Patients receive leucovorin calcium ( CF ) IV 2 hour 5-FU IV ( midpoint CF administration ) day 1 , follow UCN-01 IV 36-72 hour , week 1-3 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos 5-FU maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . The recommended phase II dose ( RPIID ) define dose precede MTD . At least 6 additional patient treat RPIID . PROJECTED ACCRUAL : A total 24 patient accrue study within 16 month .</detailed_description>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>7-hydroxystaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor metastatic unresectable standard curative palliative measure exist effective No brain metastasis primary CNS malignancy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic Bilirubin great 1.5 mg/dL AST ALT great 3 time upper limit normal Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular No known active coronary artery disease Pulmonary No pulmonary dysfunction Other HIV negative No history unusually severe and/or prolong toxicity prior therapy fluorouracil ( 5FU ) 5FU prodrugs No diabetes mellitus require insulin oral hypoglycemic therapy No ongoing active infection require IV antibiotic No serious concurrent medical illness would preclude study No psychiatric illness social situation would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy At least 4 week since prior immunotherapy recover No concurrent cytokine first course therapy Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy No concurrent systemic corticosteroid Radiotherapy At least 2 week since prior radiotherapy recover No prior pulmonary mediastinal radiation exceed 40 Gy Surgery Recovered prior surgery Other No concurrent investigational agent No concurrent cimetidine No concurrent sorivudine brivudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>